GT BiopharmaGTBP
13F holders, Q3 2024 (September 30)16holders −1
0new positions
1sold out
$28.33avg. 13F price*
At the end of Q3 2024, 16 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were DekaBank Deutsche Girozentrale ($35.1M), Bank of Montreal ($63K) and Geode Capital Management, LLC ($34K).
- Company
- GT Biopharma Inc.
- CUSIP
- 36254L308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $3 |
All 13F filers, Q2 2024 → Q3 2024: 180,366 shares bought and 14,490 shares sold, net +165,876 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| DekaBank Deutsche Girozentrale | 0.07% | Add +18.0% | 1,154,867 | $35.1M |
| Bank of Montreal | 0.00% | No change | 29,872 | $63K |
| Geode Capital Management, LLC | 0.00% | Add +34.5% | 15,041 | $34K |
| Vanguard Group Inc. | 0.00% | No change | 10,504 | $24K |
| Susquehanna International Group, LLP | 0.00% | Reduce -46.8% | 10,105 | $23K |
| Wells Fargo & Company | 0.00% | No change | 10,013 | $23K |
| BlackRock, Inc. | 0.00% | — | 9,737 | $22K |
| UBS Group AG | 0.00% | Reduce -56.5% | 3,903 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -24.4% | 1,643 | $4K |
| Morgan Stanley | 0.00% | No change | 266 | $614 |
| Bank of America Corp. | 0.00% | No change | 27 | $62 |
| Osaic Holdings, Inc. | 0.00% | No change | 12 | $28 |
| Blue Bell Private Wealth Management, LLC | 0.00% | No change | 10 | $23 |
| BNP Paribas Financial Markets | 0.00% | No change | 6 | $14 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $2 |
| Royal Bank of Canada | 0.00% | Reduce -28.6% | 5 | $0 |
"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.